The present invention can advantageously be used for the production of miglitol precursors and miglitol.
This group includes acarbose (Precose) and miglitol (Glyset).
These medications are Acarbose (Precose) and Miglitol (Glyset).
Acarbose (Precose) and miglitol (Glyset) are alpha-glucosidase inhibitors.
Drugs in this class include acarbose (Precose) and miglitol (Glyset).
Acarbose (brand name Precose) and meglitol (Glyset) are alpha-glucosidase inhibitors.
Acarbose (Precose) and meglitol (Glyset) are alpha-glucosidase inhibitors.
In addition, acarbose diminishes the insulinotropic and weight-increasing effects of sulfonylureas.
The invention relates to a tablet containing 20% to 30% miglitol, 65% to 78% insoluble constituents and tableting auxiliaries.
The present invention has valuable use in the preparation of miglitol which is a therapeutic agent for diabetes.
Drugs in this class include acarbose (Precose) and miglitol (Glyset).
The present invention relates to pharmaceutical compositions comprising voglibose, acarbose or miglitol that shall be used in the treatment of non-insulin dependent type II diabetes.
In addition, GLYSET diminishes the insulinotropic and weight-increasing effects of sulfonylureas.
There is no evidence that systemic absorption of miglitol contributes to its therapeutic effect.
These medications are Acarbose (Precose) and Miglitol (Glyset).
It belongs to a class of drugs called alpha-glucosidase inhibitors, which also includes miglitol (Glyset).
Because of the lack of extra-intestinal effects seen with Laiping, no serious systemic reactions are expected in the event of an overdose.
Because of the lack of extra-intestinal effects seen with GLYSET, no serious systemic reactions are expected in the event of an overdose.
The present invention relates to pharmaceutical sustained release formulations of α-glucosidase inhibitors as for example acarbose, miglitol, emiglitate or voglibose leading to a reduction of side effects.
As a consequence of plasma glucose reduction, miglitol reduce levels of glycosylated hemoglobin in patients with Type II (non-insulin-dependent) diabetes mellitus.
Requêtes fréquentes français :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Requêtes fréquentes anglais :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Traduction Translation Traducción Übersetzung Tradução Traduzione Traducere Vertaling Tłumaczenie Mετάφραση Oversættelse Översättning Käännös Aistriúchán Traduzzjoni Prevajanje Vertimas Tõlge Preklad Fordítás Tulkojumi Превод Překlad Prijevod 翻訳 번역 翻译 Перевод